Abstract
The main focus of this report is the MR spectroscopy of the changes in the concentration of fluorine labeled photosensitizer that occur following the IP administration. This process is studied by 19F in vivo MR methodology in a murine tumor model. The animal model used in these studies was mice bearing radiation induced fibrosarcoma (RIF) tumor on the foot dorsum. The mice were injected with a solution of ∼ 100 micro-moles of the fluorinated photosensitizer and the 19F MR examination of the photosensitizer in the tumor or the muscle was performed. The pharmacokinetic (PK) profile for each labeled compound was generated using the 19F MR data at various time points post photosensitizer administration. The pharmacokinetic parameters were analyzed and the relationship of these results to photodynamic therapy is discussed. 19F MR methods clearly demonstrate utility in measuring the pharmacokinetic profiles and provide a new approach in the evaluation of appropriate photosensitizers for use in preclinical mammalian systems.
Keywords: 19F MR, RIF tumor, pharmacokinetics, fluorine labeled photosensitizers, photodynamic therapy (PDT), photofrin
Current Drug Discovery Technologies
Title: In vivo 19F MR Studies of Fluorine Labeled Photosensitizers in a Murine Tumor Model
Volume: 4 Issue: 2
Author(s): Subbaraya Ramaprasad, Elzbieta Ripp, Joseph Missert and Ravindra K. Pandey
Affiliation:
Keywords: 19F MR, RIF tumor, pharmacokinetics, fluorine labeled photosensitizers, photodynamic therapy (PDT), photofrin
Abstract: The main focus of this report is the MR spectroscopy of the changes in the concentration of fluorine labeled photosensitizer that occur following the IP administration. This process is studied by 19F in vivo MR methodology in a murine tumor model. The animal model used in these studies was mice bearing radiation induced fibrosarcoma (RIF) tumor on the foot dorsum. The mice were injected with a solution of ∼ 100 micro-moles of the fluorinated photosensitizer and the 19F MR examination of the photosensitizer in the tumor or the muscle was performed. The pharmacokinetic (PK) profile for each labeled compound was generated using the 19F MR data at various time points post photosensitizer administration. The pharmacokinetic parameters were analyzed and the relationship of these results to photodynamic therapy is discussed. 19F MR methods clearly demonstrate utility in measuring the pharmacokinetic profiles and provide a new approach in the evaluation of appropriate photosensitizers for use in preclinical mammalian systems.
Export Options
About this article
Cite this article as:
Subbaraya Ramaprasad , Elzbieta Ripp , Joseph Missert and Ravindra K. Pandey , In vivo 19F MR Studies of Fluorine Labeled Photosensitizers in a Murine Tumor Model, Current Drug Discovery Technologies 2007; 4 (2) . https://dx.doi.org/10.2174/157016307781483423
DOI https://dx.doi.org/10.2174/157016307781483423 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Current Cancer Drug Targets Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Foldable/Expandable Gastro-retentive Films Based on Starch and Chitosan as a Carrier For Prolonged Release of Resveratrol
Current Pharmaceutical Biotechnology miR-21, miR-106b and miR-375 as Novel Potential Biomarkers for Laryngeal Squamous Cell Carcinoma
Current Pharmaceutical Biotechnology Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer
Current Pharmaceutical Design Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry